Long-term follow-up cohort of hepatitis B in China : current status and perspectives
10.3969/j.issn.1001-5256.2017.08.008
- VernacularTitle:我国乙型肝炎长期随访队列建设的现状与展望
- Author:
Xiaoyun HU
;
Jian SUN
- Keywords:
hepatitis B;
therapy;
cohort studies
- From:
Journal of Clinical Hepatology
2017;33(8):1454-1457
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a global public health issue,especially in the Asian-Pacific region.At present,entecavir,tenofovir,and pegylated interferon are the first-line antiviral drugs recommended by related guidelines for the prevention and treatment of hepatitis B;however,different national/regional policies,economic level,coverage of health insurance,and medical level have caused the difference in antiviral regimens.Therefore,we have established a long-term follow-up cohort of hepatitis B to evaluate the efficacy of different treatment regimens,in order to improve the cure rate of hepatitis B and reduce the incidence rates of liver cirrhosis,liver cancer,and end-stage liver disease.Real-world data from cohort study help to understand the differences between guidelines and clinical practice,provide a reference for HBV guidelines,and balance clinical effect and cost-effectiveness.
